Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

BofA Starts AaiPharma with 'Buy'


Banc of America initiated coverage of AaiPharma (AAII) with buy and a $25 target.

Analyst David Maris says AaiPharma has made the transition over the past several years from a historically contract-services business model to a specialty pharmaceutical model, primarily through acquisitions of branded products in the areas of pain management and critical care. As a small company making the transition, he expects likely hiccups along the way. However, the stock trades at a 40% discount to the sector average.

Maris will look for further evidence of greater organic growth and less leverage, however, he thinks the magnitude of the stock-price discount accorded to the stock is too severe, and that the earnings estimates are too low.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus